Professor, Medical Department, Huadu District People's Hospital of Guangzhou, Guangdong, PR China.
Professor, The Institute of Metabolic Diseases, Baoan Central Hospital of Shenzhen, The Fifth Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, PR China.
J Prosthet Dent. 2021 Feb;125(2):257-265. doi: 10.1016/j.prosdent.2019.12.025. Epub 2020 Mar 10.
The comparative efficacy of antifungal drugs on oral candidiasis remains unclear.
The purpose of this Bayesian network meta-analysis was to investigate the efficacy of antifungal drugs on oral candidiasis.
Databases, including PubMed, The Cochrane Library, and Web of Science, were accessed from the dates of their establishment to October, 2018, to collect randomized controlled trials (RCTs) of different antifungal drugs for oral candidiasis. A network meta-analysis was then conducted by using R and Stata 12.0 software programs.
A total of 31 RCTs involving 4042 participants were included. The meta-analysis showed that, in the treatment of oral candidiasis in reducing the mycological cure rate, itraconazole capsules, itraconazole oral solution, miconazole buccal tablets, miconazole oral gel, clotrimazole, fluconazole, ketoconazole, nystatin, and amphotericin B were better than a placebo. Miconazole oral gel, fluconazole, and ketoconazole were better than nystatin. The network meta-analysis also showed that the effects of antifungal drugs in reducing the mycological cure rate in oral candidiasis were better than those of a placebo: itraconazole capsule (OR=1.20, 95% CrI: 1.07-1.34), itraconazole oral solution (OR=1.50, 95% CrI: 1.14-1.86), miconazole buccal tablet (OR=2.80, 95% CrI: 1.20-4.50), miconazole oral gel (OR=2.90, 95% CrI: 1.70-4.30), clotrimazole (OR=3.80, 95% CrI: 1.65-5.95), fluconazole (OR=2.40, 95% CrI: 1.10-3.80), ketoconazole (OR=3.40, 95% CrI: 1.76-7.04), nystatin (OR=2.50, 95% CrI: 1.43-3.57), and amphotericin B (OR=2.60, 95% CrI: 1.91-3.29). The SUCRA values for each antifungal drug were as follows: placebo (6.80%), itraconazole capsule (51.2%), itraconazole oral solution (75.2%), miconazole buccal tablet (34.4%), miconazole oral gel (76.9%), clotrimazole (64.8%), fluconazole (79.3%), ketoconazole (50.7%), nystatin (15.7%), and amphotericin B (44.4%).
Antifungal drugs have efficacy in the treatment of oral candidiasis. The effect of fluconazole in reducing the risk of the mycological cure rate in oral candidiasis was better than that of other drugs.
抗真菌药物治疗口腔念珠菌病的疗效尚不清楚。
本贝叶斯网状meta 分析旨在研究抗真菌药物治疗口腔念珠菌病的疗效。
从各数据库建立日期至 2018 年 10 月检索PubMed、The Cochrane Library 和 Web of Science 中关于不同抗真菌药物治疗口腔念珠菌病的随机对照试验(RCT),采用 R 和 Stata 12.0 软件程序进行网状meta 分析。
共纳入 31 项 RCT 涉及 4042 名参与者。meta 分析显示,在降低口腔念珠菌病的微生物学治愈率方面,酮康唑、氟康唑、伊曲康唑胶囊、伊曲康唑口服液、克霉唑、咪康唑口腔凝胶、制霉菌素、两性霉素 B 优于安慰剂。咪康唑口腔凝胶、氟康唑和酮康唑优于制霉菌素。网状meta 分析还显示,抗真菌药物在降低口腔念珠菌病的微生物学治愈率方面优于安慰剂:酮康唑(OR=1.20,95% CrI:1.07-1.34)、伊曲康唑口服液(OR=1.50,95% CrI:1.14-1.86)、咪康唑口腔凝胶(OR=2.80,95% CrI:1.20-4.50)、克霉唑(OR=3.80,95% CrI:1.65-5.95)、氟康唑(OR=2.40,95% CrI:1.10-3.80)、酮康唑(OR=3.40,95% CrI:1.76-7.04)、制霉菌素(OR=2.50,95% CrI:1.43-3.57)、两性霉素 B(OR=2.60,95% CrI:1.91-3.29)。各抗真菌药物的 SUCRA 值如下:安慰剂(6.80%)、酮康唑(51.2%)、伊曲康唑口服液(75.2%)、咪康唑口腔凝胶(34.4%)、克霉唑(64.8%)、氟康唑(79.3%)、酮康唑(50.7%)、制霉菌素(15.7%)、两性霉素 B(44.4%)。
抗真菌药物治疗口腔念珠菌病有效。氟康唑降低口腔念珠菌病微生物学治愈率的效果优于其他药物。